menu
    • menu
    [{"orgOrder":0,"company":"Qnovia","sponsor":"Blue Ledge Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Series A Financing","leadProduct":"Nicotine","moa":"ACh receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Qnovia","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"","sponsorNew":"Qnovia \/ Blue Ledge Capital","highestDevelopmentStatusID":"4","companyTruncated":"Qnovia \/ Blue Ledge Capital"},{"orgOrder":0,"company":"Qnovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"QN-01","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Qnovia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Qnovia \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Qnovia \/ Not Applicable"},{"orgOrder":0,"company":"Qnovia","sponsor":"University of Virginia","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"QN-05","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Qnovia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Qnovia \/ University of Virginia","highestDevelopmentStatusID":"4","companyTruncated":"Qnovia \/ University of Virginia"},{"orgOrder":0,"company":"Qnovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"QN-01","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Qnovia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Qnovia \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Qnovia \/ Not Applicable"},{"orgOrder":0,"company":"Qnovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Nicotine","moa":"","graph1":null,"graph2":null,"graph3":"Qnovia","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Qnovia \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Qnovia \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Qnovia

    Menu

    Qnovia

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Qnovia

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Qnovia

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Qnovia’s RespiRx™ Inhaler IND Cleared for Smoking Cessation Therapy

                            Details : RespiRx is a drug device combination product that is the first truly inhalable nicotine replacement therapy (NRT) to assist smokers attempting to quit smoking.

                            Brand Name : RespiRx

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 01, 2024

                            Lead Product(s) : Nicotine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Qnovia

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Qnovia

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QN-01

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Qnovia, Inc. Announces Positive Results from First-In-Human Pharmacokinetic and Safety Study of Lead Asset QN-...

                            Details : QN-01 is a potential breakthrough inhalation small molecule drug therapy, which is currently being investigated for the treatment of smoking cessation.

                            Brand Name : QN-01

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 29, 2023

                            Lead Product(s) : QN-01

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Qnovia

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Qnovia

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QN-05

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Sponsor : University of Virginia

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Qnovia Enters Collaboration with University of Virginia to Advance Inhaled Drug Candidates for Treating Infect...

                            Details : The collaboration aims to advance novel inhaled-drug candidates, including QN-05 for the treatment of pneumonia and QN-06 for the treatment of pulmonary infection for individuals exposed to the biodefense agent B. anthracis, the causative agent of anthra...

                            Brand Name : QN-05

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            October 19, 2023

                            Lead Product(s) : QN-05

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Sponsor : University of Virginia

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Qnovia

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Qnovia

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QN-01

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Qnovia to Pursue UK Approval for Lead Asset QN-01 in Nicotine Replacement Therapy

                            Details : Gaining MHRA approval would validate the safety and efficacy of QN-01. The company believes it is well-positioned to expand the reach and impact of its NRT therapeutic development efforts by pursuing regulatory approval and gaining license as smoking ces...

                            Brand Name : QN-01

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 08, 2022

                            Lead Product(s) : QN-01

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Qnovia

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Qnovia

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Sponsor : Blue Ledge Capital

                            Deal Size : $17.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Qnovia, Inc. Raises $17 Million in Series A Funding to Advance Its Inhalable Therapeutics Pipeline

                            Details : The Series A proceeds will be used by Qnovia to advance its NRT drug candidate RespiRx (drud device combination having nicotine) through an IND submission with the FDA and begin human clinical trials in 2023.

                            Brand Name : RespiRx

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 28, 2022

                            Lead Product(s) : Nicotine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Sponsor : Blue Ledge Capital

                            Deal Size : $17.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth